5-HT3 antagonist 5 |
| Catalog No.GC65983 |
L'antagoniste 5-HT3 5 est un composé quinoxalin-2-carboxamide, un antagoniste des récepteurs 5-HT3. L'antagoniste 5-HT3 5 exerce un antagonisme sur l'agoniste 5-HT3 et le 2-méthyl-5-HT, et présente un effet antidépresseur chez la souris.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 901599-43-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
5-HT3 antagonist 5 is a quinoxalin-2-carboxamide compound, a 5-HT3 receptor antagonist. 5-HT3 antagonist 5 exerts antagonism on 5-HT3 agonist and 2-methyl-5-HT, and shows anti-depressant effect in mice[1].
5-HT3 antagonist 5 (compound 4c) exhibits 5-HT3 receptor antagonisms in longitudinal muscle myenteric plexus preparation from guinea pig ileum against 5-HT3 agonist, 2-methyl-5-HT, with pA2 value of 5[1].
5-HT3 antagonist 5 (compound 4c) (1 mg/kg; i.p.; single dose) decreases the duration of immobility and shows anti-depressant effect in FST mice[1].
| Animal Model: | Swiss albino mice (23 ± 2 g)[1] |
| Dosage: | 1 mg/kg |
| Administration: | Intraperitoneal injection; single dose; locomotor scores tested 10 min after administration |
| Result: | Reduced the duration of immobility as compared to the vehicle-treated (control) group. Showed no effect on the locomotion of mice as observed in spontaneous locomotor activity. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *